Although the pathogenesis of systemic sclerosis remains uncertain, a wide range of immunological abnormalities have been described in patients with the disorder. The antinuclear antibodies (ANA) and serum immune complexes are potentially the most interesting of these abnormalities, not only because they serve to identify subgroups of the disease, but also because they may be involved in the pathogenesis of at least some aspects of the disorder. Thus, although antinuclear antibodies are present in at least 90% of patients,'2 centromere antibodies are particularly associated with the CREST syndrome,3 a disease subgroup characterised by limited organ involvement and a relatively benign prognosis, while Scl 70 antibodies, which seem to be specific for systemic sclerosis, are more common in patients with systemic involvement, particularly interstitial pulmonary fibrosis. Serum immune complexes and relationship with ANA specificities. Immune complexes were positive by one or both methods in 13 (32%) sera. Neither ANA negative sera nor sera containing centromere antibodies were positive except for one serum which contained Ro and La antibodies in addition to centromere antibodies. The relationship between precipitating antibodies and immune complexes is shown in Table 2 . There was a highly significant correlation between immune complexes and antibodies to Scl 70, n-RNP, Ro, and La. Thirteen of 19 sera with these antibodies were immune complex positive compared with none of seven sera with other precipitating ANA and none of 15 sera without precipitating ANA.
Six sera were positive by both immune complex assays, including four of the five immune complex positive Scl 70 sera. Six sera were positive by the Raji cell radioimmune assay alone and one serum by the K cell inhibition assay alone.
Relationship between ANA specificity, immune complexes, and disease score. The mean disease score was higher in the patients with precipitating ANA when compared with those without (6.8 vs. Previous studies have reported variable findings with respect to the presence of serum immune complexes in SS, with an incidence of between zero and 59% of patients.4 5 1014 This finding has been explained by the use of different immune complex assays. 5 In particular the use of the Raji cell radioimmunoassay has been criticised on the grounds that nuclear antibodies as well as immune complexes may bind to the Raji cell membrane. '5 We feel that this could not account for the immune complex positive sera in this study for two reasons. Firstly, immune complexes were detected only in sera containing Scl 70, n-RNP, Ro, La antibodies, and many other sera containing precipitating and non-precipitating ANA were immune complex negative. It is of course possible that some antibody specificities bind preferentially to Raji cells, but it is notable that several sera had precipitating ANA detected by means of Raji cell extracts and were immune complex negative. These sera included all unidentified precipitating ANA and PM/Scl antibodies. Secondly, the presence of immune complexes was confirmed by an additional assay (K cell inhibition) in six of the sera. These were mainly sera with Scl 70 antibody.
4-8, p<005). The findings were very similar when
An alternative explanation for the variable findings of previous studies is that there were differences in patient groups. This could account for the finding that 44% of patients with cardiopulmonary manifestations have serum immune complexes,4 because both Scl 70 antibodies2 and immune complexes5 are particularly associated with interstitial pulmonary fibrosis. In the group of patients described here antibodies to n-RNP, Ro, and La are more common and antibodies to 
